A Phase 3, randomized, open-label study of upfront camizestrant vs standard endocrine therapy as adjuvant treatment for ER-positive/HER2negative early breast cancer with intermediate-high or high risk of recurrence (CAMBRIA-2)

被引：0
|
作者：
Loibl, Sibylle
Park, Yeon
Tolaney, Sara
Gioni, Ioanna
Johnston, Simon
Klinowska, Teresa
Mayer, Ingrid A.
Nunes, Raquel
Pistilli, Barbara
Stuart, Mary
Quintana, Angela
Walding, Andrew
Gnant, Michael
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-27-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-27-07
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2-early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
    Hamilton, Erika
    Loibl, Sibylle
    Niikura, Naoki
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Klinowska, Teresa
    Mayer, Ingrid A.
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Bachelot, Thomas
    CANCER RESEARCH, 2024, 84 (09)
  • [2] A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2-early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)
    Hamilton, E.
    Loibl, S.
    Niikura, N.
    Rastogi, P.
    Saini, K. S.
    Gioni, I.
    Klinowska, T.
    Mayer, I.
    Stuart, M.
    Syta, E.
    Walding, A.
    Bachelot, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S323 - S324
  • [3] CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2-early breast cancer
    Hamilton, Erika P.
    Loibl, Sibylle
    Bachelot, Thomas
    Gnant, Michael
    Niikura, Naoki
    Park, Yeon Hee
    Tolaney, Sara M.
    Pistilli, Barbara
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Johnston, Simon
    Nunes, Raquel
    Quintana, Angela
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Klinowska, Teresa
    Mayer, Ingrid A.
    FUTURE ONCOLOGY, 2025, 21 (07) : 795 - 806
  • [4] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer
    Rastogi, Priya
    Toi, Masakazu
    Harbeck, Nadia
    Bourayou, Nawel
    Frenzel, Martin
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (04)
  • [5] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
  • [6] ELEGANT: Elacestrant vs Standard ET in Women and Men With Node-positive, ER+, HER2-Early Breast Cancer (eBC) With High Risk of Recurrence - A Global, Multicenter, Randomized, Open- label Phase 3 Study
    Bardia, A.
    Kaklamani, V.
    O'Shaughnessy, J.
    Schmid, P.
    Beck, J. T.
    De Laurentiis, M.
    Curigliano, G.
    Rugo, H.
    Barcenas, C. H.
    Gradishar, W. J.
    Ignatiadis, M.
    Cameron, D. A.
    Tonini, G.
    Scartoni, S.
    Crozier, J.
    Nicacio, L. V.
    Wasserman, T.
    Tolaney, S. M.
    BREAST, 2025, 80
  • [7] Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Gyorffy, B.
    Ocana, A.
    Herman, P.
    Hatzis, C.
    Pandiella, A.
    Pusztai, L.
    CANCER RESEARCH, 2017, 77
  • [8] Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2-early breast cancer
    Gluz, Oleg
    Degenhardt, Tom
    Marschner, Norbert
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald
    Schinkoethe, Timo
    Graeser, Monika
    Wurstlein, Rachel
    Kuemmel, Sherko
    Harbeck, Nadia
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
    Gianni, Luca
    Bisagni, Giancarlo
    Colleoni, Marco
    Del Mastro, Lucia
    Zamagni, Claudio
    Mansutti, Mauro
    Zambetti, Milvia
    Frassoldati, Antonio
    De Fato, Raffaella
    Valagussa, Pinuccia
    Viale, Giuseppe
    LANCET ONCOLOGY, 2018, 19 (02): : 249 - 256
  • [10] ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer.
    Gluz, Oleg
    Scheffen, Iris
    Degenhardt, Tom
    Marschner, Norbert Walter
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald E.
    Schinkoethe, Timo
    Graeser, Monika Karla
    Wuerstlein, Rachel
    Kuemmel, Sherko
    Bauer, Lelia
    Schem, Christian
    Fehm, Tanja N.
    Neubauer, Hans
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345